IN2014DN10449A - - Google Patents
Info
- Publication number
- IN2014DN10449A IN2014DN10449A IN10449DEN2014A IN2014DN10449A IN 2014DN10449 A IN2014DN10449 A IN 2014DN10449A IN 10449DEN2014 A IN10449DEN2014 A IN 10449DEN2014A IN 2014DN10449 A IN2014DN10449 A IN 2014DN10449A
- Authority
- IN
- India
- Prior art keywords
- medicaments
- medicament
- substituents
- salt
- compound
- Prior art date
Links
- 239000003814 drug Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention relates to compound of the formula (I) or a salt thereof wherein the substituents are as defined in the specification; to its preparation to its use as medicament and to medicaments comprising it.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012078933 | 2012-07-20 | ||
| CN2013078309 | 2013-06-28 | ||
| PCT/IB2013/055916 WO2014013469A1 (en) | 2012-07-20 | 2013-07-18 | Carbamate/urea derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN10449A true IN2014DN10449A (en) | 2015-08-21 |
Family
ID=49263333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN10449DEN2014 IN2014DN10449A (en) | 2012-07-20 | 2013-07-18 |
Country Status (41)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR088256A1 (en) | 2011-10-08 | 2014-05-21 | Novartis Ag | CARBAMATE / UREA DERIVATIVES AS H3 RECEIVER ANTAGONISTS |
| US9034874B2 (en) | 2012-07-20 | 2015-05-19 | Novartis Ag | Carbamate/urea derivatives |
| EP3391886A1 (en) * | 2017-04-19 | 2018-10-24 | Novartis AG | The use of a h3r inverse agonist for the treatment of shift work disorder |
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| MX2021004085A (en) | 2018-10-11 | 2021-06-04 | Novartis Ag | The use of a h3r inverse agonist for the treatment of excessive daytime sleepiness associated with parkinson's disease (pd). |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| EP4251148A1 (en) | 2020-11-27 | 2023-10-04 | Richter Gedeon Nyrt. | Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2567518B1 (en) | 1984-07-11 | 1987-11-13 | Sanofi Sa | NOVEL NITROGEN HETEROCYCLIC CORE COMPOUNDS, THEIR PREPARATION AND THE MEDICINAL PRODUCTS CONTAINING THE SAME |
| TW301607B (en) | 1993-03-09 | 1997-04-01 | Takeda Pharm Industry Co Ltd | |
| US6784192B2 (en) * | 2000-01-20 | 2004-08-31 | Eisai Co., Ltd. | Piperidine compound and pharmaceutical composition thereof |
| WO2002072570A2 (en) | 2001-03-13 | 2002-09-19 | Schering Corporation | Non-imidazole compounds as histamine h3 antagonists |
| EP1631260A2 (en) | 2003-02-28 | 2006-03-08 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| CA2523431A1 (en) | 2003-04-23 | 2004-11-25 | Glaxo Group Limited | Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases |
| US7521455B2 (en) | 2004-02-13 | 2009-04-21 | Banyu Pharmaceutical Co. Ltd. | Fused ring 4-oxopyrimidine derivative |
| SE0401971D0 (en) | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidne derivatives |
| WO2006029057A1 (en) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Purification of olmesartan medoxomil |
| CN1993355A (en) | 2004-09-02 | 2007-07-04 | 特瓦制药工业有限公司 | Purification of olmesartan medoxomil |
| WO2007016496A2 (en) | 2005-08-02 | 2007-02-08 | Neurogen Corporation | Dipiperazinyl ketones and related analogues |
| CA2624625A1 (en) | 2005-11-04 | 2007-05-10 | Pfizer Limited | Tetrahydronaphthyridine derivative |
| EP1970373A1 (en) | 2005-12-02 | 2008-09-17 | Mitsubishi Tanabe Pharma Corporation | Alicyclic heterocyclic compound |
| CA2707248A1 (en) * | 2007-12-05 | 2009-06-11 | Astrazeneca Ab | New compounds ii |
| TWI498115B (en) * | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | Imidazole carbonyl compound |
| EP2328586A2 (en) | 2008-05-20 | 2011-06-08 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
| ES2601007T3 (en) | 2010-01-22 | 2017-02-13 | Taiho Pharmaceutical Co., Ltd. | Piperazine compound that has a PGDS inhibitory effect |
| TW201217312A (en) * | 2010-09-22 | 2012-05-01 | Gruenenthal Gmbh | Substituted benzamide compounds |
| AR088256A1 (en) * | 2011-10-08 | 2014-05-21 | Novartis Ag | CARBAMATE / UREA DERIVATIVES AS H3 RECEIVER ANTAGONISTS |
| US9034874B2 (en) | 2012-07-20 | 2015-05-19 | Novartis Ag | Carbamate/urea derivatives |
-
2013
- 2013-07-17 US US13/944,354 patent/US9034874B2/en active Active
- 2013-07-18 NZ NZ702346A patent/NZ702346A/en not_active IP Right Cessation
- 2013-07-18 MY MYPI2014003308A patent/MY168752A/en unknown
- 2013-07-18 MX MX2015000903A patent/MX362059B/en active IP Right Grant
- 2013-07-18 DK DK13770709.7T patent/DK2875016T3/en active
- 2013-07-18 EP EP13770709.7A patent/EP2875016B1/en active Active
- 2013-07-18 SI SI201330787T patent/SI2875016T1/en unknown
- 2013-07-18 PT PT137707097T patent/PT2875016T/en unknown
- 2013-07-18 HU HUE13770709A patent/HUE035592T2/en unknown
- 2013-07-18 EA EA201590250A patent/EA026091B1/en not_active IP Right Cessation
- 2013-07-18 ES ES13770709.7T patent/ES2648512T3/en active Active
- 2013-07-18 IN IN10449DEN2014 patent/IN2014DN10449A/en unknown
- 2013-07-18 WO PCT/IB2013/055916 patent/WO2014013469A1/en active Application Filing
- 2013-07-18 CN CN201380038422.1A patent/CN104470911B/en not_active Expired - Fee Related
- 2013-07-18 PE PE2015000045A patent/PE20151155A1/en active IP Right Grant
- 2013-07-18 HR HRP20171692TT patent/HRP20171692T1/en unknown
- 2013-07-18 CU CUP2015000006A patent/CU24248B1/en unknown
- 2013-07-18 KR KR1020157001045A patent/KR102150739B1/en not_active Expired - Fee Related
- 2013-07-18 NO NO13770709A patent/NO2875016T3/no unknown
- 2013-07-18 SG SG10201700188PA patent/SG10201700188PA/en unknown
- 2013-07-18 SG SG11201408020RA patent/SG11201408020RA/en unknown
- 2013-07-18 AU AU2013291617A patent/AU2013291617B2/en not_active Ceased
- 2013-07-18 AP AP2014008109A patent/AP3710A/en active
- 2013-07-18 JP JP2015522234A patent/JP6203841B2/en not_active Expired - Fee Related
- 2013-07-18 LT LTEP13770709.7T patent/LT2875016T/en unknown
- 2013-07-18 CA CA2878006A patent/CA2878006C/en active Active
- 2013-07-18 BR BR112015001207-8A patent/BR112015001207B1/en not_active IP Right Cessation
- 2013-07-18 PL PL13770709T patent/PL2875016T3/en unknown
- 2013-07-18 RS RS20171048A patent/RS56479B1/en unknown
- 2013-07-19 UY UY0001034921A patent/UY34921A/en unknown
- 2013-07-19 TW TW102125975A patent/TWI597276B/en not_active IP Right Cessation
- 2013-07-21 JO JOP/2013/0218A patent/JO3439B1/en active
- 2013-07-22 AR ARP130102583A patent/AR092354A1/en active IP Right Grant
-
2014
- 2014-11-27 ZA ZA2014/08805A patent/ZA201408805B/en unknown
- 2014-11-28 TN TN2014000497A patent/TN2014000497A1/en unknown
- 2014-12-05 PH PH12014502743A patent/PH12014502743A1/en unknown
-
2015
- 2015-01-09 CL CL2015000056A patent/CL2015000056A1/en unknown
- 2015-01-11 IL IL236656A patent/IL236656A/en active IP Right Grant
- 2015-01-20 GT GT201500012A patent/GT201500012A/en unknown
- 2015-01-20 CR CR20150019A patent/CR20150019A/en unknown
- 2015-01-20 CO CO15009915A patent/CO7170173A2/en unknown
- 2015-04-14 US US14/685,926 patent/US9273026B2/en active Active
-
2016
- 2016-02-22 US US15/049,739 patent/US9624192B2/en active Active
-
2017
- 2017-03-07 US US15/452,430 patent/US20170275264A1/en not_active Abandoned
- 2017-10-25 CY CY20171101112T patent/CY1119492T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN03998A (en) | ||
| NZ608116A (en) | Triazine-oxadiazoles | |
| UA116648C2 (en) | FUMARATS AS A PRODUCT AND THEIR USE IN THE TREATMENT OF DIFFERENT DISEASES | |
| MX2015008627A (en) | Boronic acid derivatives and therapeutic uses thereof. | |
| IN2014DN10449A (en) | ||
| PH12015501083B1 (en) | Novel pyridine derivatives | |
| MD20140072A2 (en) | New pyrrole compounds, process for their preparation and pharmaceutical compositions containing them | |
| PH12013501600A1 (en) | Novel heterocyclic derivatives | |
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| PH12015501843A1 (en) | Novel pyrazol derivatives | |
| IN2014DN01629A (en) | ||
| IN2015DN01119A (en) | ||
| PH12018501709A1 (en) | Naphthridinedione derivatives | |
| MY174000A (en) | Novel pyridine derivatives | |
| MX362879B (en) | Novel uses. | |
| MX2016004934A (en) | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy. | |
| PH12015500585A1 (en) | Modified hyaluronic acid derivatives and use thereof | |
| IN2014DN10669A (en) | ||
| MX363458B (en) | Novel tetrazolone derivatives. | |
| MX365192B (en) | Bendamustine derivatives and related compounds, and medical use thereof cancer therapy. | |
| MX348841B (en) | Pyrimidooxazocine derivatives as mtor - inhibitors. | |
| PH12015500373B1 (en) | Diazepinone derivatives useful for the treatment of fragile x syndrome, parkinsons or reflux disease | |
| TN2013000089A1 (en) | Triazine-oxadiazoles | |
| MA37778A1 (en) | Carbamate / urea derivatives | |
| TN2013000327A1 (en) | Novel heterocyclic derivatives |